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Summary There is increasing experimental evidence to suggest that endogenous expression of o6-
alkylguanine-DNA-alkyltransferase (ATase) is a major factor in cellular resistance to certain chemotherapeutic
agents including dacarbazine (DTIC). We have recently shown wide interindividual variation in the depletion
and subsequent regeneration of ATase in peripheral blood mononuclear cells (PMCs) following DTIC and this
has now been extended to ascertain whether or not depletion is related to dosage of DTIC used and repeated
treatment cycles of chemotherapy. ATase levels were measured in three groups of 25 patients (pts) up to 24 h
after receiving DTIC at 400 mg m-2, 500 mg m-2 or 800 mg m-2. Each group also received fotemustine
(100mgm-2), 4h after DTIC. The lowest extent of ATase depletion (highest nadir ATase) was seen in
patients receiving 400 mg m-2. The mean nadir ATase, expressed as a percentage of pre-treatment ATase, was
respectively 56.3%, 26.4% and 23.9% for 400mgm-2, 500mgm-2 and 800mgm-'. The median nadir of
ATase activity for pts receiving 800 mg m-2 pts was at 4-6 h and for pts given lower doses it was at 2-3 h. In
addition, repeated measures analysis of variance of observations before chemotherapy, then at 2, 3, 4, 6 and
18 h after chemotherapy provides some evidence that ATase was depleted to a lesser extent after cycle 1 than
after subsequent cycles (P = 0.025). It also provides evidence that the change in ATase activity over time
varied with dose and cycle. The findings can be interpreted on the basis of a dosage-dependent metabolism of
DTIC to an agent capable of methylation of DNA and subsequent depletion of PMC ATase: with higher
DTIC doses, the extent of ATase depletion may be limited by the pharmacokinetics of DTIC metabolism.
PMC ATase was measured in another group of 8 pts at various times after receiving only fotemustine
(100 mg m2) and in contrast to DTIC, no ATase depletion was seen suggesting that insufficient concen-
trations of fotemustine and/or its metabolites were available to react with DNA to produce a depletion of
PMC ATase activity.
In the treatment of metastatic melanoma, dacarbazine [5-
(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide; DTIC] is
considered the single most effective chemotherapeutic agent
available (Balch et al., 1989; Comis, 1976). It undergoes
metabolic N-demethylation to give the cytotoxic monomethyl
triazene, 5-(3-methyl- 1 -triazeno)imidazole-4-carboxamide
(MTIC) which methylates DNA, producing among 12 other
lesions, 06-methylguanine (Meer et al., 1986). There is in-
creasing evidence to suggest that 06-methylguanine is the
principal cytotoxic event following DTIC and that 06-alkyl-
guanine-DNA alkyltransferase (ATase) gene expression may
be a major factor in cellular resistance to such agents. ATase
is able to transfer the methyl group from the 06 position of
guanine to an internal cysteine residue in an auto-inactivating
stoichiometric reaction. Experimental models using ATase-
deficient cell lines or xenografts show them to be more
sensitive to DTIC than lines or xenografts with high activity
(Catapano et al., 1987; D'Incalci et al., 1988; Foster et al.,
1990; Gibson et al., 1986a; Hayward and Parsons, 1984;
Lunn & Harris, 1988). The strongest evidence for the cyto-
toxic effects of 06-alkylguanine in DNA comes from ATase
cDNA transfection experiments which show that expression
of prokaryotic or eukaryotic ATase cDNA in mammalian
cells protects them against the toxic effects to these agents
(Brennand and Margison, 1986; Jelinek et al., 1988; Kataoka
et al., 1986; Samson et al., 1986; Kaina et al., 1991).
We recently showed that there was wide interindividual
variation in the DTIC-mediated depletion and subsequent
recovery of ATase levels in human peripheral blood cells
(Lee et al., 199la) and this work has now been extended to
explore whether or not the rate and extent of depletion and
regeneration of ATase activity is related to the dosage of
DTIC used or the number of treatment cycles. Identifying the
time to reach the ATase nadir and the extent of ATase
depletion with different DTIC dosage may have important
Correspondence: S.M. Lee.
Received 20 March and in revised form 9 September 1992.
therapeutic implications especially when DTIC is combined
with the subsequent administration of a chloroethylating
nitrosourea. In this case, drug resistance appears to involve
the same ATase DNA repair enzymes which remove the
chloroethyl lesions from the 06-position of guanine, thereby
preventing the formation of a cytotoxic DNA interstrand
cross-link (see Lee et al., 1991a). Theoretically, enhanced
therapeutic effects might be obtained when the nitrosourea is
administered at the nadir of ATase activity following DTIC
treatment assuming that the effect in peripheral mononuclear
cells reflects that of tumour tissues.
Materials and methods
Patients and bloodsamples
Blood samples were collected from 30 treatment cycles of 25
pts with metastatic melanoma treated with sequential DTIC
and fotemustine chemotherapy. Approval was obtained from
the local ethical committee and all pts gave informed consent
for the study. Pts received DTIC at fixed doses (for each pt)
of 400, 500 or 800 mg m-2 by i.v. infusion followed by
fotemustine lOOmgm2, 4h later. Treatment was repeated
every 28 days and the number of cycles given depended on
the individual pts response. Blood samples were collected just
before chemotherapy and at 1, 2, 3, 4, 6 and 18 h after DTIC
infusion; in addition, 5 h samples were collected for the
400 mg m-2 patients. Blood was drawn into a 20 ml univeral
container containing 0.5% EDTA and stored at 4°C before
isolation of PMCs. Fourteen sets of samples from were also
collected from another group of 8 pts with metastatic
melanoma receiving only fotemustine (100 mgm2).
When the study was initiated, no effect of treatment cycle
on ATase concentrations was anticipated. As a result samples
were not taken from pts on the same cycles. Some pts had
samples taken on cycle 1, other on cycle 2, etc. and some pts
had samples taken on more than one cycle. In the event, the
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cycle in which ATase was measured had an effect on the
ATase level and as a result the dose and cycle effects are
confounded. To avoid this, samples were randomly selected
for each analysis so that no more than one set of observa-
tions was used from a patient. As this resulted in loss of
data, we present this aspect of the study as a guide to
possible future studies. The principal method of statistical
analysis was analysis of variance, with repeated measures
analysis of variance used for analysing the changes over time
and 'survival' analysis for estimating the time to the ATase
nadir. The computer software package BMDP was used for
most analyses.
Isolation ofmononuclear cells, ATase extraction and assay
This was carried out as described previously (Lee et al.,
1991a). Briefly, the PMCs were isolated by centrifugation on
Ficoll (Pharmacia, Uppsala, Sweden) (Boyum, 1968),
sonicated and the supernatants were assayed using [3H]-
methylated DNA containing 0.01 picomoles 06-methyl-
guanine per pg DNA. Activity was expressed as fmoles
methyl transferred to protein per mg of protein.
Measurements were in triplicate. The mean ATase values are
presented ± standard error of the mean.
Results
PMC ATase activityfollowing DTIC andfotemustine
The change in ATase activity over time was analysed using
repeated measures analysis of variance, unweighted means
method (Winer et al., 1991a). The factors used were the three
doses and the cycles, grouped as cycle 1 and cycles 2 to 6.
The level of significance was P<,0.05.
300 -
270 -
240 -
210 -
180-
E
I-
Ca
a 120- 0)
90 -
60 -
30 -
0 -
Dose effects
In the three groups of pts receiving 400, 500 and 800mg m-2
DTIC, the mean pretreatment PMC ATase levels and their
standard errors before the start of the 1st cycle were
230±16, 233+44 and 211 ± 18fmmg-' respectively. A
one-way analysis of variance revealed no statistically
significant difference (P = 0.936) and therefore subsequent
effects of ATase levels were not influenced by inadvertant
preselection bias in the dosage groups. The analysis used all
cases with measurements on cycle 1.
Following intravenous DTIC administration, progressive
depletion of ATase activity was seen (Figure 1). The changes
with time were, as expected from earlier studies (Lee et al.,,
1991a) very highly significant, but more interestingly so was
the interaction between time and dose (P<0.0001). This
shows that ATase activity changes differently over time for
different doses. The least extensive ATase depletion was
generally seen in pts receiving 400mgm2 (Figure 2). The
mean nadir ATase, expressed as a percentage of pre-
treatment ATase, was 56.3%, 26.4% and 23.9% for 400, 500
and 800 mg m-2 respectively (Figure 2) and a two way
analysis of variance, which included the effect of the two
cycle groups, confirmed that the observed difference in the
nadir between the doses of DTIC was significant at the 5%
level (P<0.005).
The time to the nadir ofATase activity was analysed like a
survival analysis and tested with the log rank test. Cases
whose lowest ATase levels were after 6 h can be considered
as 'survivors' whether or not the 18 h figure is higher: it is
not possible to indicate whether or when in the 12 h interval
the nadir has occurred and 6 h is therefore a censored time.
Pts who received 400 mg m-2 were pooled with pts who
received 500 mg m-2 so that there were enough cases in each
800 mg m-2
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Figure 1 Lymphocyte ATase activity before and after chemotherapy with 400 (o), 500 (x) or 800mgm-2 (+) DTIC. Fotemustine
was administered 4 h after DTIC. Values shown are the means ± standard error. An average of >9, 4 and 10 pts were analysed for
each time point in the 400, 500 and 800mgm2 groups, respectively.218 S.M. LEE et al.
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Figure 2 Relationship between DTIC dosage and nadir ATase
activity expressed as % of the pretreatment level. The mean
values are shown as a horizontal bar.
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group for an effective analysis and seven observations were
deleted so that no patient appeared more than once in the
analysis. The time to nadir was significantly less for pts
receiving 400 mgm2 or 500mgm2 (median 2-3 h) than
800 mg m2 (median 5-6 h) (P = 0.0407).
In less than half of the patients, there was a post nadir
increase in ATase levels by 18 h after treatment. In most
cases this was slight, ranging from 6% to 30% of the
pretreatment levels. However, in two pts receiving
400 mg m-2 and one receiving 500 mg m-2, recovery was very
extensive and rapid, attaining close to pretreatment levels: in
the former pts this was associated with an earlier ATase
nadir. In order to establish whether the increase in ATase by
18 h was statistically significant, the mean ATase at 18 h was
compared with the of the nadir. The nadir was taken as
being between 4 and 6 h at which time the means were
99.6 fm/mg and 99.4 fm mg-' respectively: the 18 h mean was
111.7fmmg-'. The difference (12.2fmmg-') was not
significant at the 5% level using the Tukey method for
comparing means (Winer et al., 199lb). Thus by 18 h the
mean ATase had not recovered and in fact in some pts the
18 h value is the lowest recorded, although this does not
necessarily indicate that it is the nadir.
Cycle effects
The mean pre-treatment ATase activity would seen to be
higher in cycle 1 (220 ± 25 fmmg-') than in cycles 2-6
(171 ± 31 gm mg-) (Figure 3). However, the P-value from
an analysis of variance is greater than 0.1. Hence the
observed difference could be due to chance. Seven observa-
tions were deleted so that no patient appeared more than
once in the analysis and the listed means were derived from
the remaining cases.
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Figure 3 Lymphocyte ATase activity before and after chemotherapy with different treatment cycles of DTIC. Values shown are
the means ± 95% confidence interval. There were 15 and 8 pts in the cycle I( +) and subsequent combined cycle (x) groups,
respectively.
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The overall difference in ATase levels between the two
cycle groups was significant (P<0.025) but the magnitude of
the difference greatly depended on the number of hours after
CT (group versus time interaction P<0.0001). This shows
that the effect of cycle changes over the sequence of
measurements. The mean nadir ATase levels were 41.7% of
the pretreatment level for cycle 1 and 29.8% for cycles 2 to 6
but the previously mentioned 2-way analysis of variance
provided inadequate evidence for an effect of cycle at the
nadir (P>0.1). The analysis and the percentages listed above
were based on 23 cases. There was no significant difference
between the cycles in the time to nadir using the log rank test
(P = 0.285).
PMC ATase activityfollowingfotemustine alone
The mean pre-treatment ATase level for pts receiving
fotemustine only was 242 ± 30 fmmg-' for cycle 1 and
176 ± 21 fmmg-' for cycles 2 and 3 combined. All pts were
given three cycles of treatment and most pts were studied on
more than one cycle, so the pts which were used in the
analysis could act as their own controls. Each patient
analysed contributed one observation only to both cycle 1
and the combined cycles 2 and 3 and the means quoted
above were for the cases used in the analysis. A Wilcoxon
paired sample test was used to test the difference between the
cycles and a P value of 0.0625 provided inadequate evidence
that the observed difference was due to anything other than
chance.
The ATase levels at 3-4 h or at 16-18 h after fotemustine
were not significantly different from the pretreatment values
(P>0.9) and there was no significant difference (P>0.9)
between ATase levels when different treatment cycles were
compared (Figure 4).
Discussion
In the present study, we were able to demonstrate DTIC-
induced depletion of ATase activity in human PMCs. This is
consistent with the metabolism of DTIC to the monomethyl
metabolite, MTIC which is produced in sufficient amounts to
react with DNA in PMCs to generate 06-methylguanine.
This is stoichiometrically repaired by ATase causing an ap-
parent decrease of PMC ATase activity. The nadir of ATase
activity generally occurred later in pts receiving 800 mg m-2
than in the lower dosage groups; pts receiving 400 mg m2
seemed to have the lowest extent of ATase depletion (highest
ATase nadir) with a mean ATase nadir of 56.3% of pretreat-
ment level. In contrast, pts receiving 500 and 800 mg m2
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DTIC had a lower mean nadir PMC activity of 26.4% and
23.9%. This suggests that the pharmacokinetics of DTIC is
dose-dependent. Indeed, it has been shown that high-dose
DTIC (850-1980 mgm-2) follows nonlinear pharmaco-
kinetics with saturation occurring in the metabolism and also
a slower distribution and disposition rate when compared to
lower dose DTIC (Breithaupt et al., 1982; Buesa &
Urrechaga, 1991; Loo et al., 1968; Skibba et al., 1969). The
later nadir in ATase activity seen with 800 mg m-2 DTIC in
contrast to 400mgm2 may be related to the more pro-
tracted production of alkylating metabolites.
Whilst ATase recovery by 18 h was generally not substan-
tial and evident in less than half of the pts, in two pts given
400mgm2, the ATase nadir was around 2 h and activity
recovered rapidly to attain close to pretreatment levels. These
results further suggest interindividual differences in the con-
tinued availability of methylating metabolites and/or in the
de novo synthesis rates for ATase. In view of the possible
saturable pharmacokinetics with high dose DTIC, it would
be clearly interesting to administer DTIC by continuous
infusion or pulsed low doses in order to assess whether or
not a complete loss ofATase activity could be achieved using
PMCs as a target.
Despite wide interindividual variations in pretreatment
levels, post-treatment DTIC-induced PMC ATase depletion
and subsequent recovery, the data suggested that ATase
depletion occurred to a lesser mean extent in treatment cycle
1 compared to subsequent treatment cycles. A similar finding
was reported in some pts treated with procarbazine (Sagher
et al., 1989). This effect might be a consequence of the initial
doses of methylating agent (or in the present case, fotemus-
tine) increasing the capacity for metabolic activation of
subsequent doses leading to increased levels of DNA methyl-
ation. If a similar increase occurred in tumour cells it might
be expected that later treatment cycles might be more thera-
peutically effective than the first cycle.
Whilst the mean pretreatment ATase activity was appar-
ently reduced in subsequent treatment cycles in comparison
to cycle 1, in the present study this was not statistically
significant and is unlikely to contribute to the differential
extent of ATase depletion in later cycles. If, however, a
reduction in the mean pre-treatment ATase levels is observed
in a larger group of pts, it might presumably be the result of
a drug-mediated selection of PMCs expressing lower levels of
ATase, although how this occurs is not clear at present.
No statistically significant change in PMC ATase activity
occurred in pts treated with lOOmgm2 fotemustine alone
although the possibility that synergistic effect on ATase
depletion might have occurred in patients given DTIC prior
to fotemustine cannot be excluded. This suggests that
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Figure 4 Mean lymphocyte ATase activity before and after chemotherapy with fotemustine alone (100 mgm-2). Values shown are
the mean ± standard error of the mean for treatment cycles 1 to 3.220 S.M. LEE et al.
insufficient concentrations of fotemustine or its metabolites
were available to react with PMC DNA to produce a detec-
table lowering of ATase activity. A similar finding was
reported for human PMCs treated with low dose BCNU
(40-200 mg m-2) although a statistically significant reduction
in PMC ATase activity was seen after high dose BCNU
(350 mg m-2) (Gerson, 1989). Experimental models have
repeatedly shown that depletion of ATase (approximately
60-90% depletion) can sensitise tumour cells to chloroethyl-
nitrosoureas, resulting in a 2- to 12- fold reduction in the
50% lethal dose of these compounds. Greater extents of
sensitisation were seen in tumour cells expressing high ATase
activity than cells with low levels of activity (Dolan et al.,
1985; Dolan et al., 1991; Gerson et al., 1985; Gibson et al.,
1986b; Zlotogorski & Erickson, 1984) If ATase is the prin-
cipal mechanism of tumour cell resistance to methylating and
chloroethylating agents and if the results obtained with PMC
can be extrapolated to tumour cells, our findings would
advocate the use of sequential DTIC then fotemustine treat-
ment (as here) rather then a schedule where DTIC and
fotemustine are administered concurrently or in which
fotemustine is given before DTIC.
Whilst such extrapolations should be considered with ap-
propriate caution, they should also be assessed in relation to
the available relevant clinical data. Thus in melanoma pts,
DTIC alone (including high dosage) regularly produces a
response rate of 20% (Balch et al., 1989; Comis, 1976;
Cowan & Bergsagel, 1971; Pritchard et al., 1980); fotemustine
alone produces a 24% response rate (Jacquillat et al., 1990).
However in pts treated with sequential DTIC and fotemus-
tine, we achieved an overall response rate of 34% and there
was a trend towards higher response rate with pts treated
with 800 mg m-2 DTIC, followed by 500 mg m-2 and
400mgm2 DTIC respectively (Aamdal et al., 1991; Lee et
al., 199lb). These results provide circumstantial evidence in
support of the use of PMC ATase levels as a monitor for
those in tumour tissues. Further support is provided by the
extent of the toxic side effects of the treatment. Thus there
was a statistically significant dosage-dependent development
of severe haematological toxicity (P<0.01) in the three
groups of pts analysed (Lee & Thatcher, unpublished data).
It is tempting to attribute this to greater DNA alkylation
with higher dosage DTIC: bone marrow has one of the lower
ATase levels of the human tissues examined so far (Gerson et
al., 1986) and this, together with the possibility that ATase
depletion might increase with treatment cycle, may account
for its greater sensitivity to the toxic effects of DTIC. Indeed
we have previously shown that ATase-deficient chloroethyl-
nitrosourea-sensitive murine haemopoietic stem cells trans-
fected with a bacterial ATase gene become highly resistant to
the toxic effects of methylating and chloroethylating agents,
strongly suggesting that ATase would protect against the
haematological effects of these agents (Jelinek et al., 1988);
other work (Dumenco et al., 1989) supports this finding.
As the bone marrow is generally the principal target organ
for the toxic side effects of these agents, it may be possible to
protect this tissue by transfection of human pluripotent stem
cells with an ATase cDNA. These cells may be returned to
the pts in the course of bone marrow transplantation. If this
achieves high levels of ATase expression, one can envisage
treating pts with high dose alkylating agents which, assuming
a linear dose response curve, might result in the elimination
of the tumour but spare the ATase transfected bone marrow
precursors.
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